Nutraceutical国际 NUTR 深 沪
已收盘 12-19 16:00:00 美东时间
0.00
-9.000
-100.00%
华盛通- 最 高0.00
- 今 开0.00
- 成交量 0股
- 最 低 0.00
- 昨 收 9.00
- 总市值 0
- 52周最高 42.45
- 市盈率 静 0.00
- 换手率 NaN.00%
- 52周最低 3.40
- 委 比 0.00%
- 总股本 --
- 历史最高 42.45
- 量 比 0
- 振 幅 0.00%
- 历史最低 3.40
- 每 手 1
- 风险率 1.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多关注全民营养需求，蒙牛在乳业研讨中展现“国家队”使命担当
（来源：衡水日报） 转自：衡水日报 9月22日，中国营养学会主办、蒙牛集团承办的"乳品科学与营养健康"分论坛在北京成功举办。中国营养学会理事长杨月欣等专家学者...
10-10 14:59
科技赋能乳业，蒙牛携手顶尖专家助力全民健康升级
来源：环球网 9月22日，由中国营养学会主办、蒙牛集团承办的“乳品科学与营养健康”分论坛在北京成功举行。作为第十七届全国营养科学大会的重要组成部分，本次论坛聚...
09-23 20:21
一周IPO观察：中慧生物/银诺医药大涨，双登股份招股，奥克斯过讯，Bullish美股上市，Gemini递表
港股IPO观察 截止2025年的第33周，港交所2家上市，1家招股，3家聆讯，8家递表。 当周上市（2家） 研发流感疫苗的生物医药公司 $中慧生物-B(02...
08-18 12:02
Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology
Nutriband Inc. announced the issuance of a U.S. patent for its AVERSA™ abuse deterrent transdermal technology, expanding intellectual property coverage in the U.S. The technology aims to prevent drug abuse, diversion, and misuse through transdermal patches. Nutriband's lead product, Aversa™ Fentanyl, has the potential to become the first abuse deterrent pain patch, with estimated annual sales reaching $80 million to $200 million.
06-09 11:30
Nutriband Inc. to present at the 2025 Noble Capital Markets Virtual Equity Conference
<p>Nutriband Inc. announces that CEO Gareth Sheridan will present at Noble Capital Markets’ virtual conference on June 5th, 4PM EST. The presentation includes a Q&A session and 1x1 investor meetings. A webcast will be available on the company’s website and Channelchek for 90 days.</p>
06-03 12:00
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl
Orlando, FL – Nutriband Inc. reported Q1 2025 revenue of $667K, up 63% YOY, driven by expansion of kinesiology tape through its Pocono Pharma subsidiary, now available at major retailers. The company advanced development of AVERSA Fentanyl, an abuse-deterrent opioid patch, through a partnership with Kindeva Drug Delivery, targeting peak US sales of $80M-$200M. Nutriband focuses on innovative transdermal pharmaceuticals, with AVERSA™ technology at its core.
06-02 12:00
